Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
about
Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronicComparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzaePharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumoniaAmoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.Eradication of Streptococcus pneumoniae in the nasopharyngeal flora of children with acute otitis media after amoxicillin-clavulanate therapy.Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatmeEfficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
P2860
Q33556653-FAFAB811-6EBB-4187-9E8F-D8401D423FEDQ33856741-6F2A1511-2ABF-4084-81C4-B9BC3DF2DA7AQ33979445-1D9EACA7-D717-4687-BAEB-23F9D7B9EBBDQ34106566-FF2FA324-D77B-40DA-864F-6C191CB6143DQ35635640-F746EE4D-64BD-42A5-81B1-0CC5C9D4712EQ37120411-E7FBE12E-8357-411D-A1B0-B86D347E9643Q37489324-1F545C0E-5CE0-4036-9FB7-9AD7EF37840EQ40166260-D03F3A28-3210-4037-89E0-AEFBEF285A22Q40968324-AE137C5B-E60E-46F5-AF05-91617E6163CE
P2860
Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@ast
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@en
type
label
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@ast
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@en
prefLabel
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@ast
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@en
P2860
P1476
Two pharmacodynamic models for ...... ns of Streptococcus pneumoniae
@en
P2093
P2860
P407
P577
1999-01-01T00:00:00Z